<DOC>
	<DOCNO>NCT01348269</DOCNO>
	<brief_summary>The primary aim test reduction bone marrow edema syndrome singular intravenous treatment Zoledronic Acid within 6 week compare placebo . The volume edema define biometric data measure use MRT six week treatment . The hypothesis check whether Zoledronic Acid efficient treatment painful bone marrow edema . A statistically significant reduction edema MRT consider evidence efficacy .</brief_summary>
	<brief_title>Assessment Efficacy Zoledronic Acid Treatment Bone Marrow Edema Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Edema</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<criteria>Men : age ≥ 18 year woman : age ≥ 18 year finish reproductivity accord follow definition : ≥ 12 month persistent natural ( spontaneous ) amenorrhoea ( woman age &lt; 50 : additionally : FSH &gt; 40MIE/ml estrogen deficiency &lt; 30pg/ml negative estrogen test ) status post hysterectomy / bilateral oophorectomy finish reproduction planning secure diagnosis bone marrow edema use MRT current osteologic basic laboratory value ( ≤ 4 week V2 ) accord DVO criterion presence personally sign informed consent participation study subchondral bone loss already occur cartilage damage due bone marrow edema reactive bone marrow edema advance arthrotic change adjacent joint ( grade III IV accord Kellgren Lawrence ) patient edematous change bone marrow due diagnosis M. Sudeck / algodystrophy / Complex Regional Pain Syndrome ( CRPS ) patient know hypo hyperparathyroidism , osteogenesis imperfecta , osteomalacia , M. Paget another systemic skeletal disease , except osteoporosis patient bone necrosis painful skeletal region patient infectious process affect bone adjacent joint adjacent soft part , respectively patient diagnose assumed rheumatoid arthritis , Lupus erythematodes , collagenosis vasculitides patient advance renal insufficiency ( GFR accord Cockcroft / Gault ≤ 40 ml/min/KO ) patient malignant disease osseous manifestation anamnesis/history status post malignant basic/primary disease large dose chemotherapy current massive dose therapy complete less 6 week ( &gt; 7.5mg prednisolon equivalent ) glucocorticoids patient malignant tumor disease within past 5 year , independent affect organ system independent implement treatment , presence relapse metastatic invasion , except basal cell carcinoma squamouscell carcinoma skin Current treatment due uveitis vague/ambiguous hyper hypocalcemia , hyper hypophosphatemia etiological vague/ambiguous APincrease symptomatic renal calculus nephrocalcinosis within 2 year V2 recent fracture within last 3 month independent localisation non consolidated fracture previous treatment i.v . bisphosphonates within last 12 month previous treatment oral bisphosphonates within last 12 month longer 3 month pretreatment prostacyclin analog ( Ilomedin® / Iloprost® ) within past 6 month Current treatment due inflammatory disease jaw area well plan tooth extraction tooth extraction less 6 month ago oral surgery implant treatment pregnancy nursing period patient immediately involved conduction trial relatives patient current proceeding relate bone marrow edema patient participation study carry increase risk consideration health condition due assessment investigator participation another clinical trial within 30 day study start trial participation patient might dependent investigator , also spouse , parent child</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>bone marrow edema</keyword>
	<keyword>Aclasta</keyword>
</DOC>